The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

FungaBeam releases an informational overview outlining how its nail fungus light device is described in company materials, including technology context, usage expectations, and safety considerations ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...

Ilumya has secured marketing authorisations from more than 55 health authorities worldwide.

Sun Pharmaceutical Industries said that the US Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab) for the ...

The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

Sun Pharmaceutical Industries Limited said on Monday, March 16, that the US Food and Drug Administration has accepted for review a supplemental Biologics License Application (sBLA) for ILUMYA.

Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can ...

Regularly taking stock of how your nails look and feel can actually be important for your overall health, too, since changes ...